Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)

Garassino, M. C.Mazieres, J.Reck, M.Chouaid, C.Bischoff, H.Reinmuth, N.Cove-Smith, L.Mansy, T.Cortinovis, D.Migliorino, M. R.Delmonte, A.Sanchez, J. GarciaVelarde, L. E. CharaBernabe, R.Paz-Ares, L.Perez, I. DiazTrunova, N.Foroutanpour, K.Faivre-Finn, C.2023-05-032023-05-032022-04-020923-7534http://hdl.handle.net/10668/21892enSafety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)conference outputopen access10.1016/j.annonc.2022.02.1351569-8041http://www.annalsofoncology.org/article/S0923753422002514/pdf778453100110